摘要
目的：了解氯丙嗪与氯氮平治疗以阳性症状为主的精神分裂症的临床疗效与副反应。方法：选择符合ＣＣＭＤ－２－Ｒ诊断标准，同时符合Ａｎｄｒｅａｓｅｎ阳性精神分裂症标准的２００例病人，随机均分为单用氯丙嗪或氯氮平治疗两组，以简明精神病量表（ＢＰＲＳ）评定疗效，以不良反应症状量表（ＴＥＳＳ）观察副反应。结果：氯丙嗪组的平均起效时间显著先于氯氮平组（Ｐ＜０．００１），其中思维障碍（因子３）和敌对性（因子５）在疗后第２周和第４周与疗前相比，氯丙嗪组效果更为显著。两组副反应有所不同。
Objective:
To compare the therapeutic and side effects of chlorpromazine (CPZ) and clozapine in the
treatment of schizophrenia. Method: 200 patients with diagnosis of schizophrenia according to
CCMD2R and positive symptoms according to SAPS by Andreason were randomly assigned to
treatment with either CPZ or clozapine for eight weeks. Clinical improvement and side effects
were monitored with the BPRS and TESS. Results: The mean response time was significantly
shorter for the CPZ than clozapine group (P<0001). Factor 3 and 4 of BPRS at second and fourth
decreased significantly more compared with pretreatment rating in the CPZ than clozapine
group(P<01). The side effects between two groups were also different. Conclusion: These
results suggest that chlorpromazine excels clozapine in the treatment of positive symptoms of
schizophrenia.
出处
《临床精神医学杂志》
1999年第3期155-156,共2页
Journal of Clinical Psychiatry
关键词
氯丙嗪
氯氮平
精神分裂症
疗效
ChlorpromazineClozapineSchizophreniaPositive symptoms
